Synthetic lipophilic antioxidant BO-653 suppresses HCV replication

被引:6
|
作者
Yasui, Fumihiko [1 ]
Sudoh, Masayuki [2 ]
Arai, Masaaki [3 ]
Kohara, Michinori [1 ]
机构
[1] Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Setagaya Ku, Tokyo 1568506, Japan
[2] Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Kanagawa, Japan
[3] Mitsubishi Tanabe Pharma Corp, Adv Med Res Labs, Dept Biol Res, Osaka, Japan
关键词
BO-653; antioxidant activity; chemical structure; HCV replication; chimeric mice; VIRUS-RNA REPLICATION; HEPATITIS-C PATIENTS; OXIDATIVE STRESS; RESVERATROL INHIBITION; CYCLOPHILIN INHIBITOR; ACTIVATES STAT-3; RIBAVIRIN; EXPRESSION; PROTEIN; DESIGN;
D O I
10.1002/jmv.23466
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The influence of the intracellular redox state on the hepatitis C virus (HCV) life cycle is poorly understood. This study demonstrated the anti-HCV activity of 2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran (BO-653), a synthetic lipophilic antioxidant, and examined whether BO-653's antioxidant activity is integral to its anti-HCV activity. The anti-HCV activity of BO-653 was investigated in HuH-7 cells bearing an HCV subgenomic replicon (FLR3-1 cells) and in HuH-7 cells infected persistently with HCV (RMT-tri cells). BO-653 inhibition of HCV replication was also compared with that of several hydrophilic and lipophilic antioxidants. BO-653 suppressed HCV replication in FLR3-1 and RMT-tri cells in a concentration-dependent manner. The lipophilic antioxidants had stronger anti-HCV activities than the hydrophilic antioxidants, and BO-653 displayed the strongest anti-HCV activity of all the antioxidants examined. Therefore, the anti-HCV activity of BO-653 was examined in chimeric mice harboring human hepatocytes infected with HCV. The combination treatment of BO-653 and polyethylene glycol-conjugated interferon-a (PEG-IFN) decreased serum HCV RNA titer more than that seen with PEG-IFN alone. These findings suggest that both the lipophilic property and the antioxidant activity of BO-653 play an important role in the inhibition of HCV replication. J. Med. Virol. 85:241249, 2013. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 49 条
  • [31] Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
    Macejak, DG
    Jensen, KL
    Jamison, SF
    Domenico, K
    Roberts, EC
    Chaudhary, N
    von Carlowitz, I
    Bellon, L
    Tong, MJ
    Conrad, A
    Pavco, PA
    Blatt, LM
    HEPATOLOGY, 2000, 31 (03) : 769 - 776
  • [32] A Small Molecule, 4-Phenylbutyric Acid, Suppresses HCV Replication via Epigenetically Induced Hepatic Hepcidin
    Kim, Kiyoon
    Lee, Young-seok
    Jeong, Suyun
    Kim, Daehong
    Chon, Suk
    Pak, Youngmi Kim
    Kim, Sungsoo
    Ha, Joohun
    Kang, Insug
    Choe, Wonchae
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 19
  • [33] Anti-malarial drug chloroquine suppresses the replication of HCV replicon via PKR-independent mechanisms
    Mizui, Tomokazu
    Yamashina, Shunhei
    Takei, Yoshiyuki
    Ikejima, Kenichi
    Kitamura, Tsuneo
    Ueno, Takashi
    Kominami, Eiki
    Watanabe, Sumio
    HEPATOLOGY, 2007, 46 (04) : 458A - 458A
  • [34] NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro
    Boerner, Joanna
    Ma, Sue
    Compton, Teresa
    Lin, Kai
    ANTIVIRAL RESEARCH, 2007, 74 (03) : A57 - A57
  • [35] NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro
    Lin, K.
    Boerner, J.
    Ma, S.
    Compton, T.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S230 - S230
  • [36] Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients
    Nozaki, Akito
    Numata, Kazushi
    Morimoto, Manabu
    Kondo, Masaaki
    Sugimori, Kazuya
    Morita, Satoshi
    Miyajima, Eiji
    Ikeda, Masanori
    Kato, Nobuyuki
    Maeda, Shin
    Tanaka, Katsuaki
    ANTIVIRAL THERAPY, 2010, 15 (08) : 1179 - 1183
  • [37] A liver-derived secretory protein, LECT2, enhances the innate immune response and suppresses HCV replication
    Shirasaki, Takayoshi
    Honda, Masao
    Murai, Kazuhisa
    Shimakami, Tetsuro
    Misu, Hirofumi
    Takarnura, Toshinari
    Kaneko, Shuichi
    CYTOKINE, 2017, 100 : 117 - 117
  • [38] A liver-derived secretory protein, LECT2, enhances the innate immune response and suppresses HCV replication
    Shirasaki, Takayoshi
    Honda, Masao
    Murai, Kazuhisa
    Shimakami, Tetsuro
    Misu, Hirofumi
    Takamura, Toshinari
    Murakami, Seishi
    Kaneko, Shuichi
    HEPATOLOGY, 2016, 64 : 738A - 739A
  • [39] HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters
    Kasai, Daisuke
    Adachi, Tetsuya
    Deng, Lin
    Nagano-Fujii, Motoko
    Sada, Kiyonao
    Ikeda, Masanori
    Kato, Nobuyuki
    Ide, Yoshi-Hiro
    Shoji, Ikuo
    Hotta, Hak
    JOURNAL OF HEPATOLOGY, 2009, 50 (05) : 883 - 894
  • [40] 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation
    Jeong, Suyun
    Lee, Young-seok
    Kim, Kiyoon
    Yoon, Ji-su
    Kim, Sungsoo
    Ha, Joohun
    Kang, Insug
    Choe, Wonchae
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)